Novavax, Inc.) has updated the terms of the previously announced collaboration and licensing agreement (CLA) with Takeda. The improved financial terms of the amended agreement for the development, manufacturing and commercialization of Nuvaxovid

Novavax, Inc. ) 已更新与武田 (Takeda) 之前宣布的合作与许可协议 (CLA) 的条款。修订后的协议在 Nuvaxovid 的开发、生产和商业化方面有更优的财务条款。

include an upfront payment, payment related to the 2024/2025 season, annual milestones associated with regulatory approvals and royalties on net sales earned every season moving forward.

包括预付款、与2024/2025赛季相关的付款、与监管批准相关的年度里程碑款项，以及从下一赛季开始每个赛季的净销售额版税。

'Our ongoing partnership with Takeda is important for Novavax and our strengthened agreement enhances our ability to operate effectively in the Japanese market,' said John C. Jacobs, President and Chief Executive Officer, Novavax. 'This partnership further validates our cutting-edge technology platform and proprietary Matrix-M.

“我们与武田持续的合作伙伴关系对诺瓦瓦克斯非常重要，我们加强的协议提升了我们在日本市场有效运作的能力，”诺瓦瓦克斯总裁兼首席执行官约翰·C·雅各布斯表示。“这一合作进一步验证了我们的尖端技术平台和专有的Matrix-M。”

adjuvant and our efforts to become a partner of choice.'

辅助性地，我们努力成为首选合作伙伴。

About Novavax

关于诺瓦瓦克斯

Novavax, Inc. (Nasdaq:

诺瓦瓦克斯医药公司（纳斯达克：

Novavax, Inc.tackles some of the world's most significant health challenges by leveraging its scientific expertise in vaccines and its cutting-edge technology platform, including protein-based nanoparticles and its Matrix-M

Novavax, Inc.利用其在疫苗方面的科学专业知识及其前沿技术平台（包括基于蛋白质的纳米颗粒及其Matrix-M）应对世界上一些最重要的健康挑战。

adjuvant. The Company's growth strategy is focused on building new and diversified partnerships via the out-licensing of its technology platform and vaccine assets earlier in the development process. These strategic collaborations are fueled by smart investments in a growing early-stage pipeline starting with the Company's core expertise in infectious disease and potentially expanding into other disease areas.

辅助剂。公司的增长战略侧重于通过在其技术平台和疫苗资产的开发过程早期进行对外授权，建立新的多样化合作伙伴关系。这些战略合作通过明智投资于不断增长的早期研发管线来推动，首先依托公司在传染病领域的核心专长，并有可能扩展到其他疾病领域。